Advertisement

Topics

Latest "Zenobia Therapeutics" News Stories - Page: 4

03:13 EST 21st November 2017 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 76–100 of 7,800+

Probably Relevant

Funding round brings in $25M for SPR Therapeutics

A round of Series C financing brought in $25 million for Cleveland-based medical device startup SPR Therapeutics.  -More- 


Finch, Crestovo combine to develop microbiome pipeline

Finch Therapeutics and Crestovo agreed to merge, forming Finch Therapeutics Group, which will focus on manufacturing candidat -More- 

Spark Therapeutics Shares Halted as FDA Committee Reviews Luxturna for Eye Disease

Spark Therapeutics (ONCE) Trading of Stock Halted as FDA Advisory Committee Reviews Investigational Gene Therapy PHILADELPHIA, Oct. 12, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging...


SPR Therapeutics secures funding to commercialise Sprint PNS system

SPR Therapeutics, a private medical device company that has developed a novel neurostimulation technology for chronic and acute pain, has announced the completion of $25m in series C financing.

iCo Therapeutics Inc. Approves Advance Notice Policy

Vancouver, British Columbia--(Newsfile Corp. - August 4, 2017) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") today announced that its board of directors has adopted an...

Company Spotlight: Flexion Therapeutics

Shares of Flexion Therapeutics Inc. (FLXN) are up 40% so far this year, well ahead of the iShares NASDAQ Biotech Index ETF (IBB), which has returned only 25% during the same period.

Deals this week: Sanofi, Entasis Therapeutics, Helsinn Therapeutics (US)

Sanofi has entered a research agreement with drug discovery services provider Axxam.

Amicus Therapeutics to drop wound healing product after Phase III failure

Amicus Therapeutics' shares rose 4.4% to $13.87 in morning trading on Wednesday, recovering from a nearly…

Sage Therapeutics FOPO nets $283.5mm to advance brexanolone in PPD

Sage Therapeutics Inc. (GABAA receptor modulators for CNS disorders) netted $283.5mm in a public offering of 3.5mm shares at ...

Company Spotlight: Spark Therapeutics

Shares of Spark Therapeutics Inc. (ONCE) have gained nearly 43% year-to-date compared to 21% rise in the iShares Nasdaq Biotechnology Index (ETF) during the same period.

Unum Therapeutics to Present New Data on its Antibody-Coupled T Cell Receptor (ACTR) Platform ...

Unum Therapeutics Inc.Jeff Michaels, +1 617-843-3820Corporate_Communications@unumrx.com Read more...

Wilson therapeutics går in i fas III

Efter lovande resultat i fas II har nu Wilson therapeutics gjort klart med FDA och EMA om nästa fas för WTX101.

Acer Therapeutics Announces Reverse Merger With Houston’s Opexa

Houston—Opexa Therapeutics is the target of a reverse merger with Acer Therapeutics, a privately held pharmaceutical company based in the Boston area. In a filing with the US Securities and Exchange Commission Monday, the companies announced the arrangement and also said that the Cambridge, MA-based Acer would receive $15.7 million in a financing round led […]

Agile Therapeutics, Inc. Hosts First Analyst Day Focused On Previewing Its Corporate Vision And Commercial Strategy

PRINCETON, N.J., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX...

BRIEF—New company targets immunotherapies for genetically-defined type 1 diabetes and other autoimmune diseases

ImmunoMolecular Therapeutics (IM Therapeutics), a company developing personalized small molecule therapies…

Amicus Therapeutics nets $243.2mm in FOPO

Amicus Therapeutics Inc. (small-molecule therapeutics for rare and orphan diseases) netted $243.2mm in a follow-on public off...

e-Therapeutics (ETX) - Sailing a steady course

Edison Investment Research - Pharmaceutical & healthcare - e-Therapeutics: e-Therapeutics’ (ETX) interim numbers demonstrate tight cost control and focus on the rationalised pipeline, with continued investment into the Network-Driven Drug Discovery platform. In the near term, we should see positive data to support out-licensing of its immuno-oncology projects. The company is well-positioned ...

Gemini Therapeutics closes $42.5M Series A for dry age-related macular degeneration therapy

Atlas Venture, Lightstone Ventures and OrbiMed co-led the Series A for the therapeutics business, which is focused on genetic causes for the condition.

Aratana Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference

LEAWOOD, Kan., Sept. 18, 2017 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, plans to present at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017 at 10:20 a.m. ET in New York City. Interested parties may ...

Immune-Onc Therapeutics, Inc. Selected to Join the Prestigious Stanford-backed StartX Community

Wednesday, June 28th 2017 at 12:08pm UTC PALO ALTO, Calif.–(BUSINESS WIRE)– Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a new biopharmaceutical company focused on advancing immuno-oncology therapeutics, announced that StartX has selected the Company and its co-founders to participate in the StartX Med Accelerator Summer 2017 Program. This is one of the world’s top startup accel...

Sanofi-Backed Voyager Therapeutics Hails Gene Therapy's Arrival

Emerging Company Profile: With a pipeline of products for neurological diseases and a collaboration with Sanofi's Genzyme, Voyager Therapeutics is...   

PTC Therapeutics fails to convince FDA panel about DMD drug

FDA advisers have voted against approval for PTC Therapeutics’ Duchenne drug Translarna because of doubts about its efficacy. The US regulator is not bound to follow the advice of its expert committees, but it usually does. One notable except...

Bioverativ, Bicycle Therapeutics Enter Research Collaboration for Rare Blood Disorders

NewsBicycle Therapeutics will be responsible for leading initial discovery activities through lead optimization to candidate selection for two programs.

Nivalis Therapeutics: Wo bleibt das "große W"?

Update zum Artikel vom 20.06.2017: (Bitte dort nachlesen, um unnötige Wiederholungen hier zu vermeiden) Zur Erinnerung: Nivalis Therapeutics (ISIN US65481J097) und Alpine Immune Sciences wollen zu ...

Pear Therapeutics Obtains FDA Clearance of the First Prescription Digital Therapeutic to Treat ...

"This is a defining moment for digital therapeutics and for patients with substance use disorder," said Corey McCann, President and Chief Executive Officer of Read more...


Quick Search
Advertisement
 

News Quicklinks